Figure 3.

Change in EuroQol-5D utility score from baseline* to 12 weeks in stage 1 (A) and from 12 weeks to final assessment in stage 2 (B)

Data are change in mean EuroQol-5D utility scores and SE, with baseline scores set to zero. *Baseline scores in stage 1 were 0·711 (SE 0·02) for amisulpride and 0·755 (0·04) for placebo. Baseline scores in stage 2 were 0·788 (0·04) for amisulpride and 0·743 (0·06) for placebo.